Cargando…

Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study

BACKGROUND: The use of warfarin in patients with non-valvular atrial fibrillation (NVAF) can be challenging. In this study, we evaluate the time in therapeutic range (TTR), health-related quality of life (HRQoL) and treatment satisfaction of patients on long-term warfarin for NVAF. The HRQoL and tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ng, Diana-Leh-Ching, Malik, Natasya Marliana Bt Abdul, Chai, Chee-Shee, Goh, Greta-Miranda-Kim-Choo, Tan, Seng-Beng, Bee, Ping-Chong, Gan, Gin-Gin, Said, Asri B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576864/ https://www.ncbi.nlm.nih.gov/pubmed/33081816 http://dx.doi.org/10.1186/s12955-020-01600-z

Ejemplares similares

Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study
por: Ng, Diana Leh-Ching, et al.
Publicado: (2019)

The willingness of parents to vaccinate their children younger than 12 years against COVID-19: a cross-sectional study in Malaysia
por: Ng, Diana-Leh-Ching, et al.
Publicado: (2022)

Clinical phenotypes and heath-related quality of life of COPD patients in a rural setting in Malaysia – a cross-sectional study
por: Chai, Chee-Shee, et al.
Publicado: (2020)

The effect of a single session of 30-min mindful breathing in reducing fatigue among patients with haematological cancer – a randomised controlled trial
por: Ng, Diana-Leh-Ching, et al.
Publicado: (2021)

COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV(1) – a post-hoc analysis of pooled data
por: Chai, Chee-Shee, et al.
Publicado: (2023)

Erectile dysfunction in male lymphoma survivors in a Southeast Asian country
por: Gan, Gin Gin, et al.
Publicado: (2021)

Clinical phenotypes of COPD and health-related quality of life: a cross-sectional study
por: Chai, Chee-Shee, et al.
Publicado: (2019)

Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
por: Nelson, Winnie W., et al.
Publicado: (2014)

Knowledge, Attitude, and Practices Among the General Population During the Later Stage of the COVID-19 Pandemic in Malaysia: A Cross-Sectional Study
por: Chai, Chee-Shee, et al.
Publicado: (2022)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Depression level and coping responses toward the movement control order and its impact on quality of life in the Malaysian community during the COVID-19 pandemic: a web-based cross-sectional study
por: Yee, Anne, et al.
Publicado: (2021)

Is Lighter Intensity of Warfarin Therapy Enough for Korean Patients with Non-Valvular Atrial Fibrillation?
por: Lee, So-Ryoung
Publicado: (2019)

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
por: Wang, Li, et al.
Publicado: (2013)

Diabetes mellitus does not negatively impact outcomes and satisfaction following unicompartmental knee arthroplasty in well-controlled disease
por: Law, Gin Way, et al.
Publicado: (2019)

A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation
por: Pengo, Vittorio, et al.
Publicado: (2015)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR
por: Çelik, Ahmet, et al.
Publicado: (2016)

Public’s Willingness to Perform COVID-19 Self-Testing During the Transition to the Endemic Phase in Malaysia – A Population-Based Cross-Sectional Study
por: Ng, Diana-Leh-Ching, et al.
Publicado: (2023)

Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study
por: Ohgushi, Atsushi, et al.
Publicado: (2016)

An observational study of international normalized ratio control according to NICE criteria in patients with non-valvular atrial fibrillation: the SAIL Warfarin Out of Range Descriptors Study (SWORDS)
por: Harris, Daniel E, et al.
Publicado: (2019)

Hydroxyurea associated ileocecal valve ulcer: evidence for causality
por: Jayaraman, Thevaraajan, et al.
Publicado: (2021)

Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
por: He, Qiyu, et al.
Publicado: (2019)

Anticoagulation Control with Acenocoumarol or Warfarin in Non-Valvular Atrial Fibrillation in Primary Care (Fantas-TIC Study)
por: Dalmau Llorca, M. Rosa, et al.
Publicado: (2021)

Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis
por: Martha, Januar Wibawa, et al.
Publicado: (2021)

Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study
por: Bo, Simona, et al.
Publicado: (2007)

How Well Does the Target INR Level Maintain in Warfarin-Treated Patients with Non-ValvularAtrial Fibrillation?
por: Kim, Jun Hyung, et al.
Publicado: (2009)

Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
por: Briasoulis, Alexandros, et al.
Publicado: (2018)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation: Meta-analysis of random control trial
por: Yu, Yi-bo, et al.
Publicado: (2018)

Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin
por: Luengsupabul, Sirote, et al.
Publicado: (2020)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D
por: Welander, Frida, et al.
Publicado: (2022)

Comparison of Direct Oral Anticoagulants and Warfarin in the Prevention of Stroke in Patients With Valvular Heart Disease: A Meta-Analysis
por: Batool, Saima, et al.
Publicado: (2022)

Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial
por: Syn, Nicholas L., et al.
Publicado: (2018)

Quality of Life of Family Caregivers of Cancer Patients in a Developing Nation
por: Gan, Gin Gin, et al.
Publicado: (2022)

Population Dynamics of Cyanomyovirus in a Tropical Eutrophic Reservoir
por: Yeo, Bee Hui, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_oa1620175s1m3g744bdtfe1tr5